1/12
07:17 am
cgon
CG Oncology (NASDAQ:CGON) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
CG Oncology (NASDAQ:CGON) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/11
08:38 am
cgon
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene [Seeking Alpha]
Low
Report
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene [Seeking Alpha]
1/10
07:02 pm
cgon
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? [Yahoo! Finance]
1/9
10:41 pm
cgon
Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? [Yahoo! Finance]
Low
Report
Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? [Yahoo! Finance]
1/9
04:07 pm
cgon
CG Oncology (NASDAQ:CGON) was given a new $93.00 price target on by analysts at Morgan Stanley.
Low
Report
CG Oncology (NASDAQ:CGON) was given a new $93.00 price target on by analysts at Morgan Stanley.
1/9
04:07 pm
cgon
CG Oncology (NASDAQ:CGON) was given a new $66.00 price target on by analysts at Truist Financial Corporation.
Low
Report
CG Oncology (NASDAQ:CGON) was given a new $66.00 price target on by analysts at Truist Financial Corporation.
1/9
08:43 am
cgon
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC [Yahoo! Finance]
High
Report
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC [Yahoo! Finance]
1/9
08:30 am
cgon
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
High
Report
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
1/8
08:42 am
cgon
CG Oncology (NASDAQ:CGON) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
CG Oncology (NASDAQ:CGON) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/6
08:00 am
cgon
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/23
04:44 am
cgon
CG Oncology Undervalued Going Into A Busy 2026 [Seeking Alpha]
Low
Report
CG Oncology Undervalued Going Into A Busy 2026 [Seeking Alpha]
12/18
08:00 am
cgon
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Low
Report
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
12/11
08:43 am
cgon
CG Oncology (NASDAQ:CGON) is now covered by analysts at Wedbush. They set an "outperform" rating and a $70.00 price target on the stock.
Low
Report
CG Oncology (NASDAQ:CGON) is now covered by analysts at Wedbush. They set an "outperform" rating and a $70.00 price target on the stock.
12/9
05:37 pm
cgon
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story [Yahoo! Finance]
Low
Report
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story [Yahoo! Finance]
12/9
12:27 am
cgon
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities [Yahoo! Finance]
Low
Report
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities [Yahoo! Finance]
12/5
08:30 am
cgon
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
Medium
Report
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
11/26
07:13 am
cgon
CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]
Low
Report
CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]
11/26
07:00 am
cgon
CG Oncology Announces New Board Member and Board Transition
Low
Report
CG Oncology Announces New Board Member and Board Transition
11/25
04:56 pm
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Yahoo! Finance]
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Yahoo! Finance]
11/25
04:05 pm
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
11/24
09:04 am
cgon
CG Oncology (NASDAQ:CGON) was given a new $62.00 price target on by analysts at Truist Financial Corporation.
Low
Report
CG Oncology (NASDAQ:CGON) was given a new $62.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
cgon
CG Oncology (NASDAQ:CGON) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
CG Oncology (NASDAQ:CGON) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/18
07:20 am
cgon
CG Oncology (NASDAQ:CGON) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
Medium
Report
CG Oncology (NASDAQ:CGON) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
11/17
08:11 am
cgon
CG Oncology (NASDAQ:CGON) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
CG Oncology (NASDAQ:CGON) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
11/15
02:18 pm
cgon
What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders [Yahoo! Finance]
Low
Report
What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders [Yahoo! Finance]